This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
JAVLE, MILIND
| Item Type | Name |
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 1
|
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 2
|
|
Concept
|
Receptors, Fibroblast Growth Factor
|
|
Academic Article
|
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
|
|
Academic Article
|
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
|
|
Academic Article
|
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
|
|
Academic Article
|
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
|
|
Academic Article
|
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
|
|
Academic Article
|
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
|
|
Academic Article
|
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
|
|
Academic Article
|
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
|
|
Academic Article
|
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
|
|
Academic Article
|
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
|